Combining Sotarasib and Panitumumab for Colorectal Cancer with KRAS G12C Mutation
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 22nd, 2024
|
In every 100 patients diagnosed with colorectal cancer, approximately 3 to 4 individuals exhibit a glycine-to-cysteine mutation at amino acid #12 of the KRAS protein. This specific genetic alteration is correlated with a dismal prognosis and a limited response to conventional therapeutic approaches. While Sotarasib, an inhibitor targeting the mutated KRAS, has demonstrated efficacy in non-small-cell lung cancer, its effectiveness has been hindered in colorectal cancer due to the development of resistance, notably through the reactivation of the epidermal growth factor receptor (EGFR) pathway. Consequently, a study, supported by Amgen funding, was undertaken to evaluate the impact of combining Sotarasib with Panitumumab, an EGFR inhibitor, in the treatment of colorectal cancer harboring the mutated KRAS G12C
The phase 3 clinical trial enrolled 160 patients previously diagnosed with metastatic colorectal cancer harboring a G12C mutation on the KRAS protein. These patients had previously been treated with fluoropyrimidine, oxaliplatin, or irinotecan but had not received any KRAS inhibitors. To assess the effectiveness of the Sotarasib-Panitumumab combination, researchers randomly assigned patients to three treatment groups. The high-dose group received 960 mg of Sotarasib orally once daily, the low-dose group received 240 mg, and both groups received Panitumumab bi-monthly via intravenous infusion at a dose of 6 mg per kilogram of body weight. The third group received the standard therapy of Trifluridine–Tipiracil or Regorafenib. Following a median follow-up of 7.8 months, the study concluded that the high-dose (960 mg) Sotarasib-Panitumumab combination resulted in a 51% lower risk of death and disease progression, while the low-dose (240 mg) group showed a 42% lower risk compared to those treated with standard therapy. Tumor shrinkage, assessed through computed tomography and magnetic resonance imaging, was observed in 26.4% of the high-dose group and 5.7% in the low-dose group. Despite the clinical benefits of the high-dose regimen, 35.8% of those receiving 960 mg Sotarasib and Panitumumab reported severe adverse events, slightly higher than the 30.2% in the 240 mg group. Noteworthy among reported effects were hypomagnesemia and skin problems. It's crucial to highlight that despite the relatively high rate of side effects, the Sotarasib and Panitumumab combination exhibited a lower rate of adverse effects compared to standard therapy.
The phase 3 clinical trial enrolled 160 patients previously diagnosed with metastatic colorectal cancer harboring a G12C mutation on the KRAS protein. These patients had previously been treated with fluoropyrimidine, oxaliplatin, or irinotecan but had not received any KRAS inhibitors. To assess the effectiveness of the Sotarasib-Panitumumab combination, researchers randomly assigned patients to three treatment groups. The high-dose group received 960 mg of Sotarasib orally once daily, the low-dose group received 240 mg, and both groups received Panitumumab bi-monthly via intravenous infusion at a dose of 6 mg per kilogram of body weight. The third group received the standard therapy of Trifluridine–Tipiracil or Regorafenib. Following a median follow-up of 7.8 months, the study concluded that the high-dose (960 mg) Sotarasib-Panitumumab combination resulted in a 51% lower risk of death and disease progression, while the low-dose (240 mg) group showed a 42% lower risk compared to those treated with standard therapy. Tumor shrinkage, assessed through computed tomography and magnetic resonance imaging, was observed in 26.4% of the high-dose group and 5.7% in the low-dose group. Despite the clinical benefits of the high-dose regimen, 35.8% of those receiving 960 mg Sotarasib and Panitumumab reported severe adverse events, slightly higher than the 30.2% in the 240 mg group. Noteworthy among reported effects were hypomagnesemia and skin problems. It's crucial to highlight that despite the relatively high rate of side effects, the Sotarasib and Panitumumab combination exhibited a lower rate of adverse effects compared to standard therapy.